PDX (Patient-Derived Xenograft) models are widely used in cancer research due to its retained features of patient’s tumor microenvironment and heterogeneity. Biocytogen uses severely immune-deficient B-NDG™ mice that are excellent host strain for PDX models. For example, compared with SCID mice, B-NDG™ mice showed higher tumor take rate and robust tumor doubling time in vivo when gastric cancer PDX was tested (Table 1). Panel A and B below als show a representative PDX tumor and PDX model growth curve.
Established PDX Models
Advantages: The severely immunodeficient B-NDG™ mice are more suitable than other immunodeficient mice for PDX model establishment. This tumor model retains high heterogeneity of tumor tissues, and tumor microenvironments are largely preserved. It overcomes the high homogeneity of traditional tumor cell line, and more closely resembles the patient’s tumor tissue.
Applications: PDX models can provide a more in-depth assessment of potential preclinical applications of new anti-tumor drugs, and are suitable for studying the mechanism of tumorigenesis.
B-NDG™ mice show significant PDX model advantages compared to scid mice
(A) The gastric cancer sample from a patient was subcutaneously implanted in a B-NDG mouse, and then palpable tumors were observed. (B) Tumor growth curve of the patient’s gastric cancer sample in B-NDG mice. (C) Comparison between CB17-scid and B-NDG mice for gastric cancer PDX model establishment.
|ID||Tumor size to 250 mm3||Tumor size to 250 mm3||Tumor doubling time|
|1||—||40 days||7 days|
|2||—||56 days||5 days|
|3||—||66 days||10 days|
|6||—||40 days||5 days|
|Tumor take rate 0%(0/6)||Tumor take rate 66.7%(4/6)||Average doubling time 6.75 days|
Case 1: PDX Model Treated with Single Agent
Efficacy Study on Triple-negative Breast Cancer PDX Models
Case 2: PDX Models Treated with Combination Therapy
PDX Models Treated with Various Combination of Agents